Hepatology Communications

Article	Citations
Issue Information	162
HBV DNA polymerase regulates tumor cell glycogen to enhance the malignancy of HCC cells	147
CD8 TRM-like T cells expressing perforin and IFN-γ define a pediatric activated T-cell acute liver failure endotype	110
Quality improvement in hepatology requires a chronic care framework	86
Association between widespread pain and associated symptoms in patients with cirrhosis	78
Clinical decision support automates care gap detection among primary care patients with nonalcoholic fatty liver disease	76
Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia	72
Immunologic landscape of human hepatic hemangiomas and epithelioid hemangioendotheliomas	67
Medical malpractice claims in Hepatology: Rates, Reasons, and Results	66
Infections in decompensated cirrhosis: Pathophysiology, management, and research agenda	66
Pain in chronic liver disease compared to other chronic conditions: Results from a contemporary nationally representative cohort study	56
Visualizing in situ viral replication across the natural history of chronic HBV infection	56
The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment?	54
Resolution of hepatic fibrosis after ZFN-mediated gene editing in the PiZ mouse model of human α1-antitrypsin deficiency	53
Development and evaluation of a virtual reality driving test for patients with cirrhosis	52
Zinc fingers and homeoboxes 2 is required for diethylnitrosamine‐induced liver tumor formation in C57BL/6 mice	51
Deletion of sphingosine 1-phosphate receptor 1 in myeloid cells reduces hepatic inflammatory macrophages and attenuates MASH	50
Increasing nonalcoholic fatty liver disease–related mortality rates in the United States from 1999 to 2022	50
Targeting hepatocyte-specific SLC2A8 blocks hepatic steatosis and dissociates TCA cycle flux inhibition from glutamine anaplerosis	50
Community-level social vulnerability and individual socioeconomic status on liver transplant referral outcome	48
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants	47
Mesenchymal stem/stromal cells armored by FGF21 ameliorate alcohol-induced liver injury through modulating polarization of macrophages	47
A genetic variant in the CD40 gene is related to HBV infection in the Chinese Han population	47
Aramchol attenuates fibrosis in mouse models of biliary fibrosis and blocks the TGFβ-induced fibroinflammatory mediators in cholangiocytes	46
Granulomatous liver diseases	46

Effect of glucagon-like peptide-1 receptor agonists on histologic MASH: A meta-analysis of randomized controlled trials	46
Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease	46
Progression of MASH to cirrhosis, decompensation, and mortality, and the utility of NITs for detection and risk stratification	45
Disproportionate increases in alcohol-associated hepatitis incidence in women and individuals of low socioeconomic status: A population-based study using the Rochester epidemiology project database	45
Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver disease (MetALD)	43
Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial	41
Erratum: Pervasive role of pruritus in impaired quality of life in patients with primary biliary cholangitis: Data from the GLIMMER study	41
Depression and anxiety management in cirrhosis	40
Copper deficiency is an independent risk factor for mortality in patients with advanced liver disease	40
Complementary and alternative medicines and liver disease	39
Management of alcohol withdrawal syndrome in patients with alcohol-associated liver disease	38
Reduced short-term survival following liver transplant in patients with acute-on-chronic liver failure: Reevaluating OPTN data	38
High prevalence of liver fibrosis among general population: a Romanian population-based study: Erratum	38
Letter to the Editor: Rifamycin SV MMX was superior to placebo, but was the comparison appropriate?	38
Hepatocyte-derived liver progenitor-like cells attenuate liver cirrhosis via induction of apoptosis in hepatic stellate cells	37
SARS-CoV-2 viral liver aggregates and scarce parenchymal infection implicate systemic disease as a driver of abnormal liver function	37
Increased MASH-associated liver cancer in younger demographics	36
CD36 in liver diseases	36
Risk-stratified surveillance for hepatocellular carcinoma	36
Hepatocellular carcinoma cells downregulate NADH:Ubiquinone Oxidoreductase Subunit B3 to maintain reactive oxygen species homeostasis	36
EBV enhances immunotherapy sensitivity in intrahepatic cholangiocarcinoma through cGAS-STING pathway activation	35
Evolutional transition of HBV genome during the persistent infection determined by single-molecule real-time sequencing	35
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals	35
Loss of heat shock factor 1 promotes hepatic stellate cell activation and drives liver fibrosis	35
Behavioral weight-loss interventions for patients with NAFLD: A systematic scoping review	35
Lumican–TLR4 interaction accelerates hepatic fibrosis by activating hepatic stellate cells	35
HBV core protein enhances WDR46 stabilization to upregulate NUSAP1 and promote HCC progression	34
CD63-high macrophage-derived exosomal miR-6876-5p promotes hepatocellular carcinoma stemness via PTEN/Akt-mediated EMT pathway	34
Fatty acid synthesis is indispensable for Kupffer cells to eliminate bacteria in ALD progression	33
Long-term protection following a primary series of hepatitis B vaccine in Alaska Native children and adults	32
Alpha-fetoprotein: Past, present, and future	32
Sirtuin3 promotes the degradation of hepatic Z alpha-1 antitrypsin through lipophagy	32
A qualitative patient interview study to understand the experience of patients with nonalcoholic steatohepatitis	32
Design, implementation, and impact of a cirrhosis-specific remote patient monitoring program	32
Progression to cirrhosis is similar among all ages in nonalcoholic fatty liver disease, but liver-related events increase with age	31
GATA4 downregulation enhances CCL20-mediated immunosuppression in hepatocellular carcinoma	30
Lipid droplet deposition in the regenerating liver: A promoter, inhibitor, or bystander?	30
Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis	30
Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC	29
A nationwide study of primary biliary cholangitis prevalence, geographic distribution, and health care providers	29
A need for confirmatory testing of isolated HBcAb-positive results in screening programs	28
Cellular communication networks in fibrosis: Insights from the MASLD pig model	28
Gut microbiota and metabolic biomarkers in metabolic dysfunction–associated steatotic liver disease	28
Midodrine versus placebo in patients with acute-on-chronic liver failure with ascites—A randomized trial (MIDAS trial)	28
Evaluation of the definition of hyperdynamic circulation in patients with cirrhosis and ascites	27
Steroid responsiveness in alcohol-associated hepatitis is linked to glucocorticoid metabolism, mitochondrial repair, and heat shock proteins	27
	27
Diet composition impacts the natural history of steatotic liver disease	27
iPSC-based hepatic organoids reveal a heterozygous MYO5B variant as driver of intrahepatic cholestasis	27
Patient-reported symptoms and interest in symptom monitoring in HCC treated with locoregional therapies: A qualitative study	27

Fecal microbiota transplantation in chronic liver disease: Current and future state of the art	26
Toll-like receptor 2 activation in monocytes contributes to systemic inflammation and alcohol-associated liver disease in humans	26
Differentiation of biliary atresia using a rapid point-of-care matrix metalloproteinase-7 assay: A multicenter diagnostic study	26
Long-term management and treatment of acute intermittent porphyria with recurring attacks using pharmacological prophylaxis	25
Erratum: Clinical spectrum and genetic causes of mitochondrial hepatopathy phenotype in children	25
Long-term weight changes are associated with initial weight changes after nonalcoholic fatty liver disease diagnosis	25
Home exercise, branched-chain amino acids, and probiotics improve frailty in cirrhosis: A randomized clinical trial	25
Repurposing of the analgesic Neurotropin for MASLD/MASH treatment	25
Thyroid hormone acts independently of the thyroid hormone receptor beta in hepatocytes to improve systemic insulin sensitivity	24
Defining the Society of Pediatric Liver Transplantation (SPLIT) research agenda: A Delphi consensus project	24
Association of preoperative IL-6 levels with overt HE in patients with cirrhosis after TIPS	24
Clinical outcomes in MetALD compared with ALD in patients referred for liver transplant evaluation	24
A randomized trial of mailed outreach with behavioral economic interventions to improve liver cancer surveillance	24
The global prevalence and impact of steatotic liver disease and viral infections: A systematic review and meta-analysis	24
Increasing national trend of direct-acting antiviral discontinuation among people treated for HCV 2016–2021	24
Dexamethasone mitigates remdesivir-induced liver toxicity in human primary hepatocytes and COVID-19 patients	24
Falls and malnutrition are associated with in-hospital mortality in patients with cirrhosis	23
CD4+ T-cell subsets in autoimmune hepatitis: A review	23
A strategy for varices screening based on acoustic radiation force impulse combined with platelet (CHESS2001): An alternative of Baveno VI criteria: Erratum	23
Erratum: Binge drinking at time of bariatric surgery is associated with liver disease, suicides, and increases long-term mortality	23
The impact of multidrug-resistant microorganisms on critically ill patients with cirrhosis in the intensive care unit: a cohort study	23
Meaningful differences in patient-reported outcome measurement scores in liver disease	23
Clinical predictors and noninvasive imaging in Fontan-associated liver disease: A systematic review and meta-analysis	23
Reply: Antibiotic prophylaxis in palliative patients with cirrhosis: Stewardship or gatekeeping?	23
Screening and management of portal hypertension and varices in cirrhosis: Expert perspectives	23
A plasma peptidomic signature reveals extracellular matrix remodeling and predicts prognosis in alcohol-associated hepatitis	23
Cost-effectiveness of HES V2.0 and GALAD for hepatocellular carcinoma surveillance in patients with cirrhosis	23
Erratum: Use and outcome of transjugular intrahepatic portosystemic shunt in hospitalized patients Germany:Nationwide study (2007-2018)	23
Reply: Hepatopulmonary syndrome associated with common variable immunodeficiency: Is it reasonable to investigate?	23
Leukemia inhibitory factor promotes human cholangiopathies, and its inhibition improves cholestasis in Abcb4 −/− mice	22
Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid	22
Acute on chronic liver failure: prognostic models and artificial intelligence applications	22
Low awareness of MASLD among U.S. adults: Trends from NHANES 2017–2023	22
Aspirin is associated with a reduced incidence of liver disease in men	22
Reproducibility of vibration-controlled transient elastography, controlled attenuation parameter, and blood tests in cirrhosis	22
An overview of the cholesterol metabolism and its proinflammatory role in the development of MASLD	22
Extracellular matrix protein 1 binds to connective tissue growth factor against liver fibrosis and ductular reaction	21
Amphisome plays a role in HBV production and release through the endosomal and autophagic pathways	21
Risk of HCC decreases in HBV-related patients with cirrhosis acquired recompensation: A retrospective study based on Baveno VII criteria	21
Impact of social determinants of health on hepatocellular carcinoma surveillance, treatment, and health care costs	21
HCC surveillance in hepatitis C: A longitudinal algorithm improves alpha-fetoprotein screening	21
Gut microbial metabolites in MASLD: Implications of mitochondrial dysfunction in the pathogenesis and treatment	21
Functional involvement of endothelial lipase in hepatitis B virus infection	21
	20
	20
Novel metabolic phenotypes for extrahepatic complication of nonalcoholic fatty liver disease: Erratum	20
A healthy lifestyle is prospectively associated with lower onset of metabolic dysfunction–associated steatotic liver disease	20
Erratum: BTLA deficiency promotes HSC activation and protects against hepatic ischemia-reperfusion injury	20
Pragmatic strategies to address health disparities along the continuum of care in chronic liver disease	20
Erratum: Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease (MASLD)	20
Hepcidin inhibits hepatocyte apoptosis through the PERK pathway in acute liver injury and fibrosis	19
The burden of extrahepatic organ failures in European patients with cirrhosis	19
Reply: Detrimental effects of diabetes mellitus in alcoholic liver disease	19
Blood bacterial DNA signatures in a prospective cohort of patients with MASLD cirrhosis	19
Heterogeneity of treatment response to beta-blockers in the treatment of portal hypertension: A systematic review	19
METTL3 inhibits liver fibrosis via RBX1 stability and TXNIP-mediated ferroptosis	19
NME2 modulates HCC progression through 4EBP1 phosphorylation and autophagy regulation independent of mTOR	19
Collagen in hepatocellular carcinoma: A novel biomarker and therapeutic target	19
Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti–HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial	19
Genetic variants associated with immune-mediated liver injury from checkpoint inhibitors	18
Deficiency of Ugcg in LSECs alleviates high-fat diet-induced MASLD	18
NUAK1 promotes metabolic dysfunction-associated steatohepatitis progression by activating Caspase 6–driven pyroptosis and inflammation	18
Hepatocyte dedifferentiation in 2D culture reveals extensive transcriptomic and proteomic rewiring	18
Mouse model of NASH that replicates key features of the human disease and progresses to fibrosis stage 3	18
The dual roles of natural killer cells in liver immunity and tolerance: Implications for health and disease	18
Gut microbiota-produced vitamin B6 mitigates alcohol-associated liver disease by attenuating hepatic oxidative stress damage	18
The most impactful findings on liver cancer in 2023	18
Severe acute hepatitis of unknown etiology in a large cohort of children	18
Adipose tissue insulin resistance exacerbates liver inflammation and fibrosis in a diet-induced NASH model	18
miR-34a regulates macrophage-associated inflammation and angiogenesis in alcohol-induced liver injury	18
Sodium cholate ameliorates nonalcoholic steatohepatitis by activation of FXR signaling	18
Clinical utility of two-step hepatitis E virus IgM antibody testing in a low-prevalence setting: A 10-year retrospective multicenter study	18
Validating new coding algorithms to improve identification of alcohol-associated and nonalcohol-associated cirrhosis hospitalizations in administrative databases	18
Zinc supplementation to improve prognosis in patients with compensated advanced chronic liver disease: a multicenter, randomized, double-blind, placebo-controlled clinical trial	18
A novel experimental model of MetALD in male mice recapitulates key features of severe alcohol-associated hepatitis	18
Epigenetic deregulation of MLF1 drives intrahepatic cholangiocarcinoma progression through EGFR/AKT and Wnt/β-catenin signaling	18
Reply: High mortality at safety-net hospitals for patients with cirrhosis	17
Outcomes of patients with acute liver failure not listed for liver transplantation: A cohort analysis	17
Dysregulated meta-organismal metabolism of aromatic amino acids in alcohol-associated liver disease	17
Neighborhood disparities and metabolic dysfunction–associated steatotic liver disease in children with overweight or obesity	17

Lysophosphatidic acid receptor 1 antagonist (EPGN2154) causes regression of NASH in preclinical NASH models	17
The impact of aging on liver health and the development of liver diseases	17
Elevated FBXL18 promotes RPS15A ubiquitination and SMAD3 activation to drive HCC	17
Low vitamin A levels are associated with liver-related mortality: a nationally representative cohort study	17
Secretion of the HBV small surface antigen is driven by an ER autophagic pathway	17
Population screening for cirrhosis	17
Interleukin-18 binding protein protects against metabolic steatohepatitis	17
The role of ammonia in chronic liver disease	17
Long-term HBV infection of engineered cultures of induced pluripotent stem cell-derived hepatocytes	17
Common variable immunodeficiency disorder-related liver disease is common and results in portal hypertension and an increased risk of death	17
Prevalence of at-risk NASH and its association with metabolic syndrome in US adults with NAFLD, 2017–2018	17
Post-translational modifications drive the effects of HMGB1 in alcohol-associated liver disease	17
ARID1A deficiency promotes malignant proliferation of hepatocellular carcinoma by activating HDAC7/ENO1 signaling pathway	17
Clinical and genetic risk factors for progressive fibrosis in metabolic dysfunction–associated steatotic liver disease	17
EGFR activation in cholangiocytes promotes extrahepatic bile duct regeneration after injury	17
Rethinking sustained recompensation in MASLD cirrhosis: The value of pharmacological maintenance	16
MAPK15 controls intracellular lipid uptake and protects mammalian liver from steatotic disease	16
Spatial and functional polarization of cancer-associated fibroblasts with CXCR4-mediated immune modulation in hepatocellular carcinoma	16
ROTEM-detected hypocoagulability is associated with major non-portal hypertensive bleeding in cirrhosis	16
Transversal psoas muscle thickness measurement is associated with response and survival in patients with HCC undergoing immunotherapy	16
Biliary microbial patterns in primary sclerosing cholangitis are linked to poorer transplant-free survival	16
The ferroptosis mediator ACSL4 fails to prevent disease progression in mouse models of MASLD	16
Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis	16
Profiling of cell‐free DNA methylation and histone signatures in pediatric NAFLD: A pilot study	16
Differential survival benefit of curative versus non-curative intent treatment in a real-world cohort with early and intermediate-stage hepatocellular carcinoma	16
Digital therapeutics lead to clinically significant body weight loss in patients with metabolic dysfunction–associated steatotic liver disease: A systematic review and meta-analysis	16
Neurogastroenterology and motility disorders in patients with cirrhosis	16
Disparities in presentation and management of chronic hepatitis B among Hispanics in a diverse safety net system	16
HBV-specific T-cell function is nonenhanced by tenofovir-induced decline in HBV viremia or HBsAg titer in chronic hepatitis B	16
Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus	16
	16
Predicting hepatic encephalopathy in patients with cirrhosis: A UK population–based study and validation of risk scores	16
Novel biomarkers for early detection of HCC in patients with MASLD or ALD	16
Aerobic exercise interventions lead to MASH resolution in clinical trials: Pooled analysis using the MASH resolution index	15
Evidence-based criteria for identifying at-risk individuals requiring liver disease screening	15
Assessing the risk of surgery in patients with cirrhosis	15
Incidence, clinical characteristics, and risk factors associated with recurrent alcohol-associated hepatitis	15
Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known	15
Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction–associated steatohepatitis	15
Microbially conjugated bile salts found in human bile activate the bile salt receptors TGR5 and FXR	15
Incidence and diagnostic yield of repeat imaging–based screening for hepatic arteriovenous malformations in patients with HHT	15
A versatile method to profile hepatitis B virus DNA integration	15
Portal cavernoma cholangiopathy: A systematic review of current understanding, clinical significance, and management	15
Modulating intestinal neuroimmune VIPergic signaling attenuates the reduction in ILC3-derived IL-22 and hepatic steatosis in MASLD	15
An optimized peritonitis-induced ACLF model that reproduces the full spectrum of extrahepatic organ failures in mice	15
Long-term outcomes after ICU admission in critically ill patients with liver cirrhosis: An Australian state-wide cohort study	14
Erratum: Community-level social vulnerability and individual socioeconomic status on liver transplant referral outcome	14
Learn, adapt, act: A pragmatic approach for intervening on disparities in hepatocellular carcinoma outcomes	14
Nicotinamide riboside enhances liver regeneration via the MCART1/ASB3 axis in obesity-compromised rats	14
Loss of phospholipase Cγ1 suppresses hepatocellular carcinogenesis through blockade of STAT3‐mediated cancer development	14
The incidence and predictors of false-negative pancreatobiliary fluorescence in situ hybridization (PB-FISH) in biliary strictures: A prospective study	14
Major Shifts in Outpatient Cirrhosis Care Delivery Attributable to the COVID‐19 Pandemic: A National Cohort Study	14
Spermidine enhances the efficacy of adjuvant in HBV vaccination in mice	14
Hepatocellular carcinoma in Fontan-associated liver disease: Incidence, risk stratification, and surveillance implications	14
Clinical outcomes of intrahepatic cholestasis of pregnancy with versus without chronic hepatitis B: A retrospective analysis	14
Farnesoid X receptor alpha ligands inhibit HDV in vitro replication and virion infectivity	14
Symptom burden and treatment patterns in primary biliary cholangitis: A systematic review and meta-analysis	14
Baveno VII for HCC: Are we there yet?	14
HMOX1+ macrophages determine immunosuppressive microenvironment and immunotherapy efficacy in hepatocellular carcinoma	14
Cytomegalovirus infection in patients with biliary atresia—further questions and possible solutions	14
Erratum: Live-smart: A sequential, multiple assignment randomized trial to reduce falls in cirrhosis	14
Liver iron levels are associated with HFE-hemochromatosis genotype, diet, adiposity, and disease in the UK Biobank	14
Problematic alcohol use and its impact on liver disease quality of life in a multicenter study of patients with cirrhosis	13
Role of mitogens in normal and pathological liver regeneration	13
Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study	13
High prevalence of short telomeres in idiopathic porto-sinusoidal vascular disorder	13
A nationwide assessment of hepatocellular adenoma resection: Indications and pathological discordance	13
HCV direct acting antiviral treatment leads to highly durable rates of ALT and AST lower than 30/19 criteria and improved APRI and FIB‐4 scores	13
Validation of MELD 3.0 in 2 centers from different continents	13
Ethanol disrupts hepatocellular lipophagy by altering Rab5-centric LD-lysosome trafficking	13
Cellular communication network factor 1‐stimulated liver macrophage efferocytosis drives hepatic stellate cell activation and liver fibrosis	13
Efficacy, safety, and pharmacokinetics of rifaximin in pediatric patients with hepatic encephalopathy in Japan: An open-label study	13
Maternal Western diet is associated with distinct preclinical pediatric NAFLD phenotypes in juvenile nonhuman primate offspring	13
Financial burden in a US cohort of patients with HCC	13
Sarcopenia is associated with osteopenia and impaired quality of life in children with genetic intrahepatic cholestatic liver disease	13
Reply: Validation of MELD 3.0 in 2 centers from different continents	13
Spatial transcriptomics supports a role for SOX4-driven signaling throughout the disease course of biliary atresia	13
Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies	13
Issue Information	13
Deletion of adipocyte prohibitin 1 exacerbates high‐fat diet‐induced steatosis but not liver inflammation and fibrosis	13
GALAD outperforms aMAP and ALBI for predicting HCC in patients with compensated advanced chronic liver disease: A 12-year prospective study	13
ICIs in hepatocellular carcinoma: A comprehensive analysis of path forward for multimodal treatment strategies	12
Distinct immune surveillance in primary biliary cholangitis and primary sclerosing cholangitis is linked with discrete cholangiocarcinoma risk	12
Missense variants in the TRPM7 α-kinase domain are associated with recurrent pediatric acute liver failure	12
Reply: Critical commentary on the study comparing TIPS, tunneled peritoneal catheter, and ascites pump in refractory ascites	12
Accuracy of the “Surprise Question” in predicting 90-day mortality among hospitalized patients with decompensated cirrhosis	12
Mannose reduces fructose metabolism and reverses MASH in human liver slices and murine models in vivo	12
Ultrasound of the rectus femoris as a novel tool to measure sarcopenia in pediatric chronic liver disease	12
Elevated bile acids are associated with left ventricular structural changes in biliary atresia	12
Reply—Examining pregnancy outcomes in alcohol-associated hepatitis: A call for further research	12
Reply: Baveno VII for HCC—Are we there yet?	12
Risk of injuries before and after a diagnosis of cirrhosis: A population-based cohort study	12
Rbpj deletion in hepatic progenitor cells attenuates endothelial responses and fibrosis in DDC-fed mice	12
Artificial intelligence-based clinical decision support for liver transplant evaluation and considerations about fairness: A qualitative study	12
Health economic outcomes of a minimal monitoring approach to providing HCV therapy	12